Stephanie Graff, MD, FACP, FASCO· @DrSGraff · X·· 21 小时前评分70
正文 · 原文
VIKTORIA-1 shows benefit of Gedatolisib + fulvestrant +/- palbociclib significantly improved median PFS across subgroups as compared to alpelisb+fulv (in second line after CDK4/6i) #ESMO26 @OncoAlert @BarbaraPistill2
137 浏览 · 5 赞 · 4 转发 · 0 回复
会议摘要
LBA16按 Rapid oral 1: Breast cancer, advanced stage 对上
VIKTORIA-1: Updated results of a randomized, open-label, phase 3 study of gedatolisib (geda) + fulvestrant (fulv) ± palbociclib (palbo) vs standard of care in patients (pts) with HR+/HER2- advanced breast cancer (ABC) (Study 2)
https://esmocongress.esmo.org来源：Stephanie Graff, MD, FACP, FASCO · x.com